
1993-09-20
Small
0personInquired
0personFavorited
ConnectType:
T - Technology & Patents
Industry:
Pharmaceuticals and Chemical Intermediates
Country / Region:
China
Company Type:
Listed company
Registered Capital:
250 million RMB
Company Capability: Process Technology Development、Chemical Technology & Patents、Technology Transfer
Aim Honesty Biopharmaceutical Co., Ltd. ., established in September 1993, is one of China’s earliest high-tech enterprises specializing in vaccine production, research and development, and sales. The company’s registered capital is RMB 250 million. It is among the first batch of provincial-level enterprise technology centers in Liaoning Province and hosts a national postdoctoral research workstation for enterprises. The company is located in Dalian, a picturesque coastal city, at No. 35 Wandal Road, Dalian Economic & Technological Development Zone. More than half of its employees possess educational backgrounds in pharmaceuticals or related fields.
The company’s primary products include recombinant hepatitis B vaccine (Hansenula polymorpha yeast). The hepatitis B vaccine is a major national scientific and technological project under the State’s 863 Program. Its production facility covers over 11,000 square meters and has an annual production capacity of up to 45 million doses. The vaccine utilizes a domestically pioneered, internationally advanced recombinant Hansenula polymorpha yeast expression technology platform, featuring high yield and high antigen purity, ensuring reliable safety and suitability for broader population groups. Consequently, it enjoys exceptional brand recognition and market influence.
The company is currently strengthening industry-academia-research collaboration with renowned domestic and international institutions, leveraging existing technological advantages to conduct in-depth development and expand scale and strength. Aimei Chengxin is committed to building a genetic engineering vaccine platform technology.
We believe that these new vaccine products will successively enter the market in the near future. Vaccine manufacturing constitutes a health undertaking vital to public welfare; as a biopharmaceutical vaccine enterprise, Aimei Chengxin shoulders the social mission of safeguarding national public health and the well-being of the general populace. Past, present, and future, Aimei Chengxin strives to become a pillar enterprise within China’s biological vaccine industry. We will continue refining our existing products, persistently strengthen R&D on novel products, continuously broaden and deepen our product portfolio, while simultaneously pursuing cutting-edge global biotechnology advancements and applying modern biotechnologies to develop more and better products—thus achieving win-win outcomes for both the company and its customers, contributing proactively to national disease prevention and control initiatives, and enhancing the quality of human life.
Connect
More Suppliers科林能源技术(北京)有限公司
77
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp
凯铭科技(杭州)有限公司
79
0
T - Technology & Patents
P - Procurement
Dalian Pace Gas Equipment Co., Ltd.
112
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp





































